These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 9618691)

  • 21. The Case for Selective Patent Foramen Ovale Closure After Cryptogenic Stroke.
    Wiktor DM; Carroll JD
    Circ Cardiovasc Interv; 2018 Mar; 11(3):e004152. PubMed ID: 29870380
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Does transcatheter closure of patent foramen ovale really "shut the door?" A prospective study with transcranial Doppler.
    Anzola GP; Morandi E; Casilli F; Onorato E
    Stroke; 2004 Sep; 35(9):2140-4. PubMed ID: 15284445
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Transcatheter closure of patent foramen ovale associated with paradoxical embolism using the amplatzer PFO occluder: initial and intermediate-term results of the U.S. multicenter clinical trial.
    Hong TE; Thaler D; Brorson J; Heitschmidt M; Hijazi ZM;
    Catheter Cardiovasc Interv; 2003 Dec; 60(4):524-8. PubMed ID: 14624434
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Transcatheter Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke: A Meta-Analysis of Randomized Controlled Trials.
    Darmoch F; Al-Khadra Y; Soud M; Fanari Z; Alraies MC
    Cerebrovasc Dis; 2018; 45(3-4):162-169. PubMed ID: 29597192
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Long-term follow-up after PFO device closure: Outcomes and Complications in a Single-center Experience.
    Taggart NW; Reeder GS; Lennon RJ; Slusser JP; Freund MA; Cabalka AK; Cetta F; Hagler DJ
    Catheter Cardiovasc Interv; 2017 Jan; 89(1):124-133. PubMed ID: 27027873
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patent foramen ovale transcatheter closure vs. medical therapy on recurrent vascular events: a systematic review and meta-analysis of randomized controlled trials.
    Rengifo-Moreno P; Palacios IF; Junpaparp P; Witzke CF; Morris DL; Romero-Corral A
    Eur Heart J; 2013 Nov; 34(43):3342-52. PubMed ID: 23847132
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stroke recurrence in patients with patent foramen ovale: the Lausanne Study. Lausanne Stroke with Paradoxal Embolism Study Group.
    Bogousslavsky J; Garazi S; Jeanrenaud X; Aebischer N; Van Melle G
    Neurology; 1996 May; 46(5):1301-5. PubMed ID: 8628471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of medical treatment with percutaneous closure of patent foramen ovale in patients with cryptogenic stroke.
    Windecker S; Wahl A; Nedeltchev K; Arnold M; Schwerzmann M; Seiler C; Mattle HP; Meier B
    J Am Coll Cardiol; 2004 Aug; 44(4):750-8. PubMed ID: 15312853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Study design of the CLOSURE I Trial: a prospective, multicenter, randomized, controlled trial to evaluate the safety and efficacy of the STARFlex septal closure system versus best medical therapy in patients with stroke or transient ischemic attack due to presumed paradoxical embolism through a patent foramen ovale.
    Furlan AJ; Reisman M; Massaro J; Mauri L; Adams H; Albers GW; Felberg R; Herrmann H; Kar S; Landzberg M; Raizner A; Wechsler L;
    Stroke; 2010 Dec; 41(12):2872-83. PubMed ID: 21051670
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A meta-analysis of transcatheter closure of patent foramen ovale versus medical therapy for prevention of recurrent thromboembolic events in patients with cryptogenic cerebrovascular events.
    Pineda AM; Nascimento FO; Yang SC; Kirtane AJ; Sommer RJ; Beohar N
    Catheter Cardiovasc Interv; 2013 Nov; 82(6):968-75. PubMed ID: 23832613
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patent Foramen Ovale Closure or Anticoagulation vs. Antiplatelets after Stroke.
    Mas JL; Derumeaux G; Guillon B; Massardier E; Hosseini H; Mechtouff L; Arquizan C; Béjot Y; Vuillier F; Detante O; Guidoux C; Canaple S; Vaduva C; Dequatre-Ponchelle N; Sibon I; Garnier P; Ferrier A; Timsit S; Robinet-Borgomano E; Sablot D; Lacour JC; Zuber M; Favrole P; Pinel JF; Apoil M; Reiner P; Lefebvre C; Guérin P; Piot C; Rossi R; Dubois-Randé JL; Eicher JC; Meneveau N; Lusson JR; Bertrand B; Schleich JM; Godart F; Thambo JB; Leborgne L; Michel P; Pierard L; Turc G; Barthelet M; Charles-Nelson A; Weimar C; Moulin T; Juliard JM; Chatellier G;
    N Engl J Med; 2017 Sep; 377(11):1011-1021. PubMed ID: 28902593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term efficacy of transcatheter patent foramen ovale closure on migraine headache with aura and recurrent stroke.
    Giardini A; Donti A; Formigari R; Salomone L; Palareti G; Guidetti D; Picchio FM
    Catheter Cardiovasc Interv; 2006 Apr; 67(4):625-9. PubMed ID: 16548006
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transient cerebral ischemia in an elderly patient with patent foramen ovale and atrial septal aneurysm.
    Merante A; Gareri P; Castagna A; Marigliano NM; Candigliota M; Ferraro A; Ruotolo G
    Clin Interv Aging; 2015; 10():1445-9. PubMed ID: 26379429
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Interventional closure of patent foramen ovale with Nit-occlud® device in prevention of recurrent neurologic events-Long-term results.
    Araszkiewicz A; Sławek S; Trojnarska O; Lesiak M; Grygier M
    Catheter Cardiovasc Interv; 2018 Jul; 92(1):159-164. PubMed ID: 29068141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of Percutaneous Closure of Interatrial Shunts on Migraine Attacks: Single-Operator Series and Review of the Literature.
    Manolis AS
    Rev Recent Clin Trials; 2017; 12(2):129-138. PubMed ID: 28356032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interventional closure with Amplatzer PFO occluder of patent foramen ovale in patients with paradoxical cerebral embolism.
    Chatterjee T; Petzsch M; Ince H; Rehders TC; Körber T; Weber F; Schneider H; Auf der Maur C; Nienaber CA
    J Interv Cardiol; 2005 Jun; 18(3):173-9. PubMed ID: 15966921
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement.
    Hung J; Landzberg MJ; Jenkins KJ; King ME; Lock JE; Palacios IF; Lang P
    J Am Coll Cardiol; 2000 Apr; 35(5):1311-6. PubMed ID: 10758974
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of results of percutaneous closure of patent foramen ovale for paradoxical embolism in patients with versus without thrombophilia.
    Giardini A; Donti A; Formigari R; Bronzetti G; Prandstraller D; Bonvicini M; Palareti G; Guidetti D; Gaddi O; Picchio FM
    Am J Cardiol; 2004 Oct; 94(8):1012-6. PubMed ID: 15476614
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Surgical closure of patent foramen ovale in patients with suspected paradoxical embolism: long-term results.
    Gasiavelis N; Grinnemo KH; Lindblom D; Dellgren G
    Scand Cardiovasc J; 2004 Dec; 38(6):375-9. PubMed ID: 15804806
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Percutaneous closure of patent foramen ovale in patients with paradoxical embolism: long-term risk of recurrent thromboembolic events.
    Windecker S; Wahl A; Chatterjee T; Garachemani A; Eberli FR; Seiler C; Meier B
    Circulation; 2000 Feb; 101(8):893-8. PubMed ID: 10694529
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.